Health and Healthcare
FDA Accepts Allergan and Paratek's Newest Acne Treatment for Review
Published:
Last Updated:
Shares of Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) saw a handy gain on Thursday after the firm announced in conjunction with Allergan PLC (NYSE: AGN) that the U.S. Food and Drug Administration (FDA) accepted their New Drug Application (NDA). Specifically, the NDA is for the review of Seysara (sarecycline) for the treatment of moderate to severe acne vulgaris in patients nine years of age and older.
The application includes two Phase 3 studies, which demonstrated that sarecycline significantly improved acne severity based on Investigator’s Global Assessment (IGA) success and significantly reduced inflammatory lesion count versus the placebo at week 12. Back in March 2017, Allergan announced positive results of these Phase 3 studies, which met their primary efficacy endpoints.
Allergan completed the NDA submission in October 2017 and expects the Prescription Drug User Fee Act (PDUFA) action date to occur in the second half of 2018.
In terms of ownership, Allergan has U.S. rights to the development and commercialization of Seysara, while Paratek retains all ex-U.S. rights.
David Nicholson, chief research and development officer at Allergan, commented:
We are pleased that the FDA has accepted our application and look forward to advancing our conversations toward a potential U.S. approval of Seysara in the second half of 2018. This milestone reinforces our commitment to advancing research and bringing new therapies to patients, and our dermatology customers.
Evan Loh, MD, president, COO and chief medical officer of Paratek, added:
The FDA’s NDA acceptance is encouraging as results shown in the Seysara (sarecycline) Phase 3 trials involving 2,002 patients demonstrate that Seysara if approved, has the potential to be a new, effective, safe and well-tolerated treatment option for physicians treating patients with moderate to severe acne.
Shares of Allergan traded up 1% at $167.48 on Thursday, with a consensus analyst price target of $226.81 and a 52-week range of $160.07 to $256.80.
Paratek traded up 5.5% at $18.73 a share, with a 52-week range of $13.20 to $29.00 and a consensus price target of $3.80.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
